AbCellera Biologics Inc. ABCL Equity Method Investments
Equity Method Investments at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s equity method investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s equity method investments?
- AbCellera Biologics Inc. (ABCL) reported equity method investments of $32.5M in Q1 2026.
- How has AbCellera Biologics Inc.'s equity method investments changed year-over-year?
- AbCellera Biologics Inc.'s equity method investments increased by 0.6% year-over-year, from $32.3M to $32.5M.
- What is the long-term trend for AbCellera Biologics Inc.'s equity method investments?
- Over 5 years (2020 to 2025), AbCellera Biologics Inc.'s equity method investments has grown at a 11.0% compound annual growth rate (CAGR), from $19.25M to $32.5M.
- What does equity method investments mean?
- Investments in unconsolidated affiliates and joint ventures where the company has significant influence (typically 20-50% ownership), carried at proportional book value.